Double Digit Income per Share rise by 19.23 % at the Food Processing company amid the financial time-frame ending May 01 2022

Decline in Earnings while Revenues grew at the Socket Mobile Inc. amid the fiscal second quarter of 2022

Revenue growth of 1.564 %, could not prevent income decline of -96.3 % in the Jun 30 2022 report, compared to same reporting season a year before. Revenues were at $6.05 millions and eps at $0.01.

For the financial period ending June 30 2022 Icosavax Inc. decreased loss per share of $-0.57 per share compare to $-2.86 a year ago and EPS improved from $-0.60 per share from the preceding quarter.

Revenues remained unaffected to $0.00 millions from $1.90 millions in the corresponding quarter a year ago and sequentially Revenue decreased from $0.58 millions.

Blank Checks company, deterioration in the corporate behavior all over financial span ending second quarter of 2022

The shareholders did not hope for any modifications at the revenue all over the April to June 30 2022 reporting season at the company. However, stockholders consider ADEXs' operating loss which has been at $-0.54352 millions, during the same period.

Critical quarter for Biora Therapeutics Inc. over the financial second quarter of 2022

For the most recent fiscal period Biora Therapeutics Inc. decreased loss per share of $-0.03 per share compare to $-1.23 a year before and Income per Share improved from $-0.08 per share from the prior financial reporting period.

Revenues went down sharply by -77.538 % to $0.10 millions from $0.46 millions in the similar financial reporting period a year before and sequentially Revenue decreased by -2.804 % from $0.11 millions.

Loss on Weak Sales the company amid the second quarter of 2022

For the financial second quarter of 2022 Sorrento Therapeutics Inc. lost money of $-0.54 per share compare to $-0.57 a year ago and grew deficit from $-0.12 per share from the prior reporting period.

Revenues decreased widely by -15.173 % to $11.46 millions from $13.51 millions in the same reporting period a year ago and sequentially Revenue Tumbled by -37.661 % from $18.39 millions.

Lucira Health Inc. announced that the company went from strength to strength, in the most recent fiscal period

LHDX announced very robust Revenue advance of 110.194 % year on year to $26.15 millions in the most recent fiscal period, but increased a deficit per share at $-0.54.

Iridex Corp declared a sensible Revenues enhancement, in the second quarter of 2022

For the financial span ending July 02 2022 IRIX Deficit has swelled of $-0.14 per share compare to $0.09 a year before and EPS improved from $-0.15 per share from the preceding quarter.

Revenue grew barely by 2.45 % to $13.76 millions from $13.43 millions in the corresponding quarter a year before and sequentially Revenues surged by 2.749 % from $13.39 millions.

The company published Revenue of $41.359 millions, in the financial span ending June 30 2022

Biote Corp. revealed $41.359 millions, in Revenue in the most recent fiscal period.

For the most recent fiscal period company had turn a round to earnings by displaying Income per Share of $1.32 per share compare to $-0.19 a year ago and EPS turned positive from $-0.15 per share from the prior reporting period.

Revenues remained unaltered to $-0.00 millions from $34.38 millions in the corresponding reporting period a year ago and sequentially Revenues surged from $38.35 millions.